Synko Topping

Manufacturer: Artra-Synkoloid Product Category: Pipe Insulation Asbestos Type: Chrysotile Years Produced: 1962–Early 1980s Legal Classification: Tier 2 — Litigated Product

Product Description

Synko Topping was a finishing and topping compound manufactured by Artra-Synkoloid, a company that produced a range of construction and industrial materials throughout the mid-to-late twentieth century. During the period spanning from approximately 1962 through the early 1980s, Synko Topping was formulated and sold for use in industrial settings, where it served as a surface finishing material applied over base-coat insulation systems on pipes and other mechanical equipment.

Products in this category were common in the industrial construction market during this era, when asbestos-containing materials were widely considered industry-standard for thermal insulation and finishing applications. Synko Topping was designed to provide a smooth, hard finish layer over insulated pipe systems, protecting the underlying insulation from mechanical damage, moisture, and environmental degradation while contributing to the overall thermal performance of the insulation assembly. These topping compounds were marketed and sold to industrial facilities, including power plants, refineries, chemical plants, shipyards, and manufacturing operations, where extensive pipe networks required insulation and finishing.

Artra-Synkoloid marketed products under the Synko brand through various periods of the company’s operation. The Synko product line encompassed multiple compound formulations intended for different phases of installation work, and Synko Topping represented the finishing stage of pipe insulation systems that workers applied in the field.

Asbestos Content

Synko Topping contained chrysotile asbestos, the most commonly used variety of asbestos in commercial and industrial products throughout the twentieth century. Chrysotile, sometimes referred to as “white asbestos,” is a serpentine mineral fiber that was prized in manufacturing for its heat resistance, tensile strength, binding properties, and flexibility. When incorporated into topping and finishing compounds, chrysotile fibers helped create a durable, crack-resistant surface coating capable of withstanding the thermal cycling and mechanical stress associated with industrial pipe systems.

In pipe insulation topping compounds of this type, chrysotile fibers were typically mixed into a wet slurry or paste formulation along with binders, fillers, and other additives. Once applied and dried, the finished product formed a rigid shell that locked the fibers into a hardened matrix. However, any subsequent disturbance of the cured material — through cutting, sanding, scraping, or demolition — had the potential to release those bound fibers back into the air as respirable dust.

The U.S. Environmental Protection Agency’s Asbestos Hazard Emergency Response Act (AHERA) and Occupational Safety and Health Administration (OSHA) regulations have long recognized chrysotile asbestos as a human carcinogen. OSHA’s asbestos standards establish permissible exposure limits and require specific engineering controls and respiratory protection when workers disturb asbestos-containing materials, reflecting the documented health risks associated with chrysotile fiber inhalation. There is no established safe level of asbestos exposure.

How Workers Were Exposed

Industrial workers who handled, applied, or later disturbed Synko Topping during the product’s years of production and use faced potential exposure to airborne chrysotile asbestos fibers. The exposure pathways associated with this type of pipe insulation topping compound were varied and arose at multiple stages of a product’s lifecycle.

During the mixing and application phase, workers who prepared Synko Topping from dry or partially dry components could disturb the asbestos-containing material before it was fully wetted and set. Mixing dry compound, pouring material, and troweling or hand-applying the product to pipe surfaces could generate dust containing respirable asbestos fibers. In facilities without adequate ventilation or respiratory protection — conditions that were common before OSHA’s asbestos standards were strengthened in subsequent decades — workers could inhale significant quantities of airborne fibers during routine application tasks.

Industrial workers in facilities where Synko Topping had previously been applied also faced secondary or bystander exposure when the cured material was disturbed by maintenance, repair, or renovation activities. Cutting into insulated pipe sections, removing old topping to access underlying insulation, chipping or scraping degraded surface coatings, and demolishing or replacing piping systems all had the potential to release chrysotile fibers from hardened compound. Workers in adjacent areas who were not directly performing insulation work could nonetheless inhale fibers that became airborne during nearby disturbance activities.

The industrial settings where Synko Topping was typically used — power generation facilities, petroleum refineries, chemical processing plants, shipbuilding yards, and heavy manufacturing operations — frequently involved large quantities of insulated piping and employed significant numbers of tradespeople and general industrial workers in close proximity. In such environments, asbestos dust generated by one trade or work activity could affect workers across a broad area.

Litigation records document that plaintiffs who alleged exposure to Synko Topping and similar Artra-Synkoloid products worked in a range of industrial occupations and environments during the decades when these materials were in active use. Plaintiffs alleged that they were not adequately warned of the health hazards associated with asbestos-containing products and that manufacturers knew or should have known of those risks before warnings were provided.

Documented Trust Fund / Legal Options

Synko Topping is a Tier 2 litigated product. Artra-Synkoloid has not established a dedicated asbestos bankruptcy trust fund from which claimants can seek compensation through an administrative claims process. As a result, individuals who were exposed to Synko Topping and have developed asbestos-related diseases must pursue compensation through civil litigation rather than through a trust fund filing.

Litigation records document claims against Artra-Synkoloid and related entities by individuals who alleged occupational exposure to Synko Topping and other asbestos-containing products in the company’s line. Plaintiffs alleged that exposure to chrysotile asbestos fibers released during the handling and disturbance of Synko Topping contributed to the development of serious asbestos-related diseases, including mesothelioma, asbestosis, and lung cancer.

Individuals who believe they were exposed to Synko Topping or other Artra-Synkoloid asbestos-containing products and who have subsequently received a diagnosis of an asbestos-related illness are encouraged to consult with an attorney who specializes in asbestos litigation. Experienced asbestos attorneys can evaluate the specific facts of a potential claim, identify all responsible parties — which may include multiple manufacturers, distributors, premises owners, and contractors — and determine what legal avenues are available based on the individual’s work history, exposure circumstances, and medical diagnosis.

Additionally, individuals who were exposed to multiple asbestos-containing products in the course of their careers — which is common among industrial workers who worked in facilities where numerous asbestos products were used simultaneously — may also be eligible to file claims with one or more asbestos bankruptcy trusts established by other manufacturers whose products were present in the same worksites. An asbestos attorney can conduct a full exposure analysis to identify all potential sources of recovery.

Asbestos-related diseases typically have long latency periods of ten to fifty years between initial exposure and diagnosis. Statutes of limitations for asbestos claims vary by state and generally begin to run from the date of diagnosis or discovery of the illness, not from the date of exposure. Timely legal consultation following a diagnosis is essential to preserving all available legal rights.